| 中文名称Chinese name
|
HIV-1 BaL-1 (R5 tropic)阴道途径感染RAG-hu小鼠模型 |
| 编号Model number |
|
| 英文名称English name |
HIV-1 BaL-1 (R5 tropic) intravaginally infected RAG-hu mouse model |
| 物种Species name |
小鼠
|
| 品系Strain name |
|
| 人类疾病Human diseases |
HIV |
| 传染性Infectivity |
是 |
| 微生物Microorganism |
|
| 类别Category |
HIV感染动物模型 |
| 造模因素Modeling factors |
|
| 制作方法Making method |
Humanized BALB/c-Rag22/2cc2/2 (RAG-hu) mice construction: newborn mice were conditioned by irradiating with 350 rads and then injected intrahepatically with 0.5-16106 human CD34+ cells. Mice were
screened for human cell engraftment at 10–12 weeks postreconstitution. Raltergravir (Isentress) 400 mg, Merck & Co) were freshly dissolved in distilled water each day prior to oral gavage. Mouse
equivalent drug doses were calculated by using an interspecies allometric scaling factor of 12.3 to arrive at 164 mg/kg and 62 mg/kg doses for raltegravir and maraviroc respectively. Mice were challenged with HIV-1 vaginally on the 4th day of treatment and the drug treatment continued for 3 more days. For vaginal viral challenges, cell-free HIV-1 strain BaL-1 (R5 tropic virus) contained in the original media used to produce the virus (RPMI 1640 medium supplemented with 10% fetal bovine serum) was used. Vaginal infections were performed in a volume of 20 ml (3000 TCID of BaL-1 virus). |
| 生物学特征Biological characteristics |
|
| 医学用途Medical use |
用于HIV致病机制研究、疫苗和药物评估。 |
| 临床表现Clinical manifestation |
|
| 病理表现Pathology |
|
| 发病天数Days of onset |
|
| 发病过程Pathogenesis process |
|
| 临床诊断Clinical diagnosis |
病毒在血液中复制 |
| 评价模型成功的指标Indicators for evaluating model success |
|
| 保藏单位Preservation unit |
科罗拉多州立大学@@https://www.colostate.edu/ |
| 参考文献Reference |
Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model,PMID:21203568,DOI:10.1371/journal.pone.0015257 |
| 录入/更新时间Date |
2021.7.20 |
| 备注Remarks |
|
当前位置：
